A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Proxinium Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease

Trial Profile

A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Proxinium Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms TARGET
  • Sponsors Viventia Biotechnologies
  • Most Recent Events

    • 09 Apr 2008 Status change from recruiting to discontinued, as reported by clinicaltrials.gov.
    • 29 Jan 2008 The first efficacy assessment is expected to be available in the first quarter of 2009.
    • 29 Jan 2008 The trial is approximately 50% enrolled, with complete enrolment expected in the third quarter of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top